Morphic Medical

First Risk-Benefit Data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry

First Risk-Benefit Data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry

First Risk-Benefit Data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry

The effects of EndoBarrier therapy on glycaemic control, weight and blood pressure are likely to reduce the complications of type 2 diabetes. This 1st international data from the EndoBarrier worldwide registry suggests that the likely benefits of EndoBarrier treatment, far outweigh the risks.

Videos

How RESET Works

Maintenance of Efficacy After RESET

BBC News Item

DJBL for the treatment of type 2 diabetes and obesity: EASD 2022